Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.96−0.22 (-3.06%)
Close on Nov 13, 2026Market cap $459.71MP/E –Yield –
Evolus ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Evolus's ebitda for the twelve months ending Sep 30, 2026 was -$7.89M. For fiscal 2025 it was -$25.16M. The highest annual figure on record is -$11.51M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.16M | – |
| FY2024 | Dec 31, 2024 | -$29.11M | – |
| FY2023 | Dec 31, 2023 | -$44.10M | – |
| FY2022 | Dec 31, 2022 | -$61.61M | – |
| FY2021 | Dec 31, 2021 | -$38.78M | – |
| FY2020 | Dec 31, 2020 | -$146.04M | – |
| FY2019 | Dec 31, 2019 | -$94.82M | – |
| FY2018 | Dec 31, 2018 | -$46.13M | – |
| FY2017 | Dec 31, 2017 | -$11.51M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.85M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.50M | – |
| Q4 FY2025 | Dec 31, 2025 | $6.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$940.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.26M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.98M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.53M | -244.4% |
| Q4 FY2021 | Dec 31, 2021 | -$17.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.19M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.55M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$106.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.08M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.94M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.02M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.79M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.10M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.62M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.17M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.87M | – |
See a number that looks wrong?